Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy

Anonymous (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on reccurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet, 365 (9472), 1687-1717.Search in Google Scholar

De Laurentiis, M., Caputo, F., Massarelli, E., Forestieri, V., Vernaglia, A., Carlomagno, C., Lauria, R., Bianco, A. R., De Placido, S. (2001). HER2 expression and anthracycline effect: Results from the Naple GUN 3 randomized trial. Proc. Am. Soc. Clin. Oncol., 20, 34A (abstract 133).Search in Google Scholar

Dressler, L. G., Berry, D. A., Broadwater, G., Cowan, D., Cox, K., Griffin, S., Miller, A., Tse, J., Novotny, D., Persons, D. L., Barcos, M., Henderson, I. C., Liu, E. T., Thor, A., Budman, D., Muss, H., Norton, L., Hayes, D. F. (2005). Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J. Clin. Oncol., 23(19), 4287-4297.10.1200/JCO.2005.11.012Search in Google Scholar

Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol., 10(7), 1049-1056.Search in Google Scholar

Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S. (2001). Induction of topoisomerase II activity after Erb B2 activation is associated with a differential response to breast cancer chemotherapy. Clin. Cancer Res., 7(6), 1497-1504.Search in Google Scholar

Jarvinen, T. A., Liu, E. T. (2003). HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res. Treat., 78(3), 299-311.10.1023/A:1023077507295Search in Google Scholar

Jarvinen, T. A. H., Tanner, M., Rantonen, V., Barlund, M., Borg, A., Grénman, S., Isola, J. (2000). Amplification and deletion of topoisomerase II associate with Erb B-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Amer. J. Pathol., 156(3), 839-847.10.1016/S0002-9440(10)64952-8Search in Google Scholar

Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdottir, K., Olsen, K. E., Mouridsen, H., Ejlertsen, B. (2005). Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J. Clin. Oncol., 23(30), 7483-7490.10.1200/JCO.2005.11.00716234514Search in Google Scholar

Konecny, G., Fritz, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H., Slamon, D., Pegram, M. (2001). HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res. Treat., 69(1), 53-63.10.1023/A:1012226006395Search in Google Scholar

Levine, M. N., Bramwell, H., Pritchard, K. I., Shepherd, L. E., Tu, D., Paul, N. (1998). Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol., 16(22), 2651-2658.10.1200/JCO.1998.16.8.26519704715Search in Google Scholar

Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., Wolmark, N. (1998). erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst., 90(18), 1361-1370.10.1093/jnci/90.18.13619747867Search in Google Scholar

Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15(5), 537-547.10.1038/sj.onc.12012229247307Search in Google Scholar

Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H. (2007). Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol., 25(25), 3808-3815.10.1200/JCO.2006.10.497617664460Search in Google Scholar

Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., Levine, M. N. (2006). HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med., 354(20), 2103-2111.10.1056/NEJMoa05450416707747Search in Google Scholar

Slamon, D. J., Godolphin, W., Jones, J. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., Press, M. F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712.Search in Google Scholar

Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Lager, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J. Clin. Oncol., 25(1), 118-145.10.1200/JCO.2006.09.277517159189Search in Google Scholar